Imatinib Denk

Imatinib, the active ingredient in Imatinib Denk, is a protein kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting specific molecular pathways that drive disease progression.

GNH USA supplies Imatinib Denk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Denk is used to target malignancies driven by abnormal tyrosine‑kinase activity, particularly in hematologic and solid‑tumor settings.

- Chronic Myeloid Leukemia: reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal Stromal Tumor: inhibits tumor growth and delays disease progression. - Philadelphia‑positive Acute Lymphoblastic Leukemia: provides targeted therapy to achieve remission in eligible patients.

Imatinib may cause a range of adverse reactions, from mild to severe. Monitoring and prompt reporting of symptoms are essential for safe use.

Common Side Effects: - Nausea and vomiting: mild gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools. - Muscle cramps: intermittent muscle tightness. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice. - Cardiotoxicity: reduced left‑ventricular ejection fraction. - Severe neutropenia: increased infection risk. - Hemorrhage: abnormal bleeding or bruising. - Pulmonary arterial hypertension: shortness of breath and fatigue. - Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, clinicians should assess patient history and baseline laboratory values to mitigate risks. - Baseline labs: obtain complete blood count and liver function tests. - Cardiac monitoring: evaluate cardiac function in patients with pre‑existing heart disease. - Drug interactions: review concomitant medications for potential CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits clearly outweigh risks. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Imatinib can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic levels. - Antacids containing aluminum or magnesium: can decrease absorption.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly affect bioavailability. - Warfarin: monitor INR for potential anticoagulation changes. - CYP2C8 substrates (e.g., repaglinide): adjust dose if needed.